September 2012

With the ability to provide non-invasive, three dimensional, and quantitative data; PET, SPECT, and fluorescence imaging (FMT) enable translational imaging of biodistribution, molecular and cellular targeting, competitive binding and PK/PD. These imaging applications have become critical assays for biologics characterization for discovery screening, lead candidate selection, optimization and safety. The use of imaging-based biodistribution applications is advancing rapidly, both with industry demand and access to radiochemistry facilities and expertise.

During this webinar Dr. Pat McConville, CSO of Molecular Imaging, Inc., reviewed the dual labeling and imaging strategy and related challenges of biodistribution studies. He also provided an overview of the key imaging technologies involved, and how these technologies can be accessed and used to drive key decision-making associated with assessment of biologics targeting and biodistribution. Dr. Vosjan of BV Cyclotron VU in the Netherlands offered an overview of immuno-PET imaging of targeting and non-invasive biodistribution. She also focused on zirconium-89 and iodine-124 PET based detection and imaging of labeled antibodies, including preclinical and clinical imaging success stories.